CCWM
ACAD icon

Cassaday & Co Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cassaday & Co Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.3K Hold
840
– – ﹤0.01% 764
2026
Q1 		$18.7K Buy
+840
New +$20.1K ﹤0.01% 797

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cassaday & Co Wealth Management's ACAD Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 840 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Cassaday & Co Wealth Management first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Cassaday & Co Wealth Management held 840 shares of Acadia Pharmaceuticals worth $21.3K as of Q2 2026.
  • Cassaday & Co Wealth Management left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #764 holding.
  • Cassaday & Co Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.